Navigation Links
The Sturdier Sex?: Study by Pittsburgh Scientists Finds Female Stem,Cells Work Better

Stem Cells Isolated from Females Regenerate Skeletal Muscle More Efficiently than Male Cells

PITTSBURGH, April 09, 2007 /PRNewswire/ -- Female stem cells derived from muscle have a greater ability to regenerate skeletal muscle tissue than male cells, according to a study at Children's Hospital of Pittsburgh of UPMC.

The study, which is being published in the April 9 issue of the Journal of Cell Biology, is the first ever to report a difference in regenerative capabilities of muscle stem cells based on sex.

This finding could have a major impact on the successful development of stem cells as viable therapies for a variety of diseases and conditions, according to the study's senior author, Johnny Huard, PhD, director of the Stem Cell Research Center at Children's and the Henry J. Mankin Professor and Vice Chair for Research in the Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine.

"Regardless of the sex of the host, the implantation of female stem cells led to significantly better skeletal muscle regeneration," said Dr. Huard, also the deputy director of the McGowan Institute of Regenerative Medicine. "Based on these results, future studies investigating regenerative medicine should consider the sex of the stem cells to be an important factor. Furthermore, investigations such as ours could lead to a better understanding of sex-related differences in aging and disease and could explain, at least partially, the high variability and conflicting results reported in the literature on stem cell biology."

Dr. Huard's team, and the study's first author, Bridget Deasy, PhD, director of the Live Cell Imaging Lab at Children's Stem Cell Research Center, made the discovery while working with a population of stem cells they isolated in the lab while searching for a cure for Duchene muscular dystrophy (DMD). DMD is a genetic disease estimated to affect one in every 3,500 boys. Patients with DMD lack dystrophin, a protein that gives muscle cells structure. Using an animal model of the disease, his laboratory is using stem cells to deliver dystrophin to muscles.

In this study, Dr. Huard's team injected female and male muscle-derived stem cells into dystrophic mice and then measured the cells' ability to regenerate dystrophin-expressing muscle fibers.

They then calculated the regeneration index (RI) -- the ratio of dystrophin-positive fibers per 100,000 donor cells. Only one of the 10 male populations of implanted stem cells had an RI over 200. In contrast, 40 percent of the female stem cell populations had an RI higher than 200, and 60 percent of the female populations of stem cells had an RI higher than the mean RI of the male cells (95).

This difference may arise from innate sex-related differences in the cells' stress responses, according to Dr. Deasy, an assistant professor in the Departments of Orthopaedic Surgery and Bioengineering at the University of Pittsburgh School of Medicine and School of Engineering, respectively.

The investigators examined several aspects of stem cell behavior. They screened for differences in thousands of genes, and they also looked for differences related to estrogen. In many ways the male and female stem cells were similar, Dr. Deasy said.

"The major difference was what we observed after exposing the cells to stress or after cell transplantation in the animals that have muscular dystrophy. Transplantation of female cells leads to a much more significant level of skeletal muscle regeneration," she said. "The male cells exhibited increased differentiation after exposure to oxidative stress, which may lead to cell depletion and a proliferative advantage for female cells after cell transplantation."

Dr. Huard is an internationally recognized cell biologist conducting laboratory research into the therapeutic use of stem cells to treat a variety of musculoskeletal and orthopedic diseases and injuries. In the lab, Dr. Huard is developing cutting-edge therapies to regenerate bone and cartilage and to repair damaged muscle. The application of these therapies could range from the repair of heart muscle damaged by heart attack to the repair of sports-related bone, cartilage and muscle injuries.

For more information about Dr. Huard's research, please visit http://www.chp.edu.

Pittsburgh of UPMC

CONTACT: Marc Lukasiak, +1-412-692-7919, +1-412-692-5016,, or James Swyers, +1-412-647-3555, ,both of Children's Hospital of Pittsburgh of UPMC Marc.Lukasiak@chp.edu Swyersjp@upmc.edu

Web site: http://www.chp.edu//

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... a startling report released today, National Safety Council research ... proven plan to eliminate prescription opioid overdoses. Prescription Nation ... tackling the worst drug crisis in recorded U.S. history, assigned a ... , New Mexico , Tennessee ... failing states, three – Michigan , ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating ... many ways they remain in the eye of the beholder, according to experts who ... of The American Journal of Managed Care. For the full issue, click here ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):